Navigation Links
ASCO in Medical News

MDOUTLOOK(R) Quick Polls Report on Clinical Integration of Key Oncology Developments Following ASCO 2009

ATLANTA, June 24 /PRNewswire/ -- MDOUTLOOK(R), the innovative oncology intelligence platform, today announced the results from its Quick Poll research, which was launched immediately following this month's annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida. Base...

Prometheus Presents Proprietary Oncology Diagnostic Platform at ASCO Annual Meeting

New Product Names for Recently Introduced MicroRNA-based Diagnostics Also Unveiled SAN DIEGO, June 1 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, presented an overview of its proprietary oncology diagnostic platform yesterday at the American...

Telik Presents Results at ASCO From ASSIST-5 Trial of TELCYTA in Platinum Refractory and Resistant Ovarian Cancer

PALO ALTO, Calif., May 31 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) today announced presentation at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, of results from the ASSIST-5 Phase 3 randomized, multinational study of TELCYTA(...

Wyeth Donates $100,000 to ASCO Cancer Foundation(R) to Support Cancer Prevention and Care

COLLEGEVILLE, Pa., May 30 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), has donated $100,000 to The American Society of Clinical Oncology (ASCO) Cancer Foundation to help support its efforts to advance cancer research, provide patients with important health i...

2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com

ORLANDO, Fla., May 28 /PRNewswire/ -- As a service to journalists and other critical audiences around the world, PR Newswire will be posting event related news releases from participating companies issued via PR Newswire into a dedicated event news archive for this event. (Logo: http://www...

Rexin-G Controls Tumor Growth and Improves Survival in Chemotherapy-Resistant Sarcoma and Osteosarcoma: Phase I/II and Phase II Studies, ASCO 2009

SAN MARINO, Calif., May 18 /PRNewswire/ -- Epeius Biotechnologies ( www.epeiusbiotech.com ) today announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rex...

Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009

Data Include First Presentation of Phase III Progression Free Survival Results for Pazopanib in Kidney Cancer LONDON and PHILADELPHIA, May 11 /PRNewswire/ -- GlaxoSmithKline (GSK) Oncology announced that new clinical data from nine of its oncology molecules will be featured in various pre...

Impac Software Selected to Present at the Electronic Health Records Lab During 2009 ASCO Annual Meeting

SUNNYVALE, Calif., May 8 /PRNewswire/ -- Impac Software, part of the Elekta Group, has been selected to present at the Electronic Health Records (EHR) Lab during the 2009 American Society of Clinical Oncology's (ASCO) Annual Meeting, May 29 - June 2, at the Orange County Convention Center, in Orla...

Previstage(TM) GCC to be presented at ASCO GI

Ticker Symbol: CUR QUEBEC CITY, Jan. 12 /PRNewswire-FirstCall/ - DiagnoCure Inc. (TSX: CUR), a life sciences company commercializing high-value cancer diagnostic tests and delivering lab services, and its wholly-owned subsidiary, DiagnoCure Oncology Laboratories based in West Chester, PA, nea...

Olympic Champion Mary Lou Retton and ASCO Join Frosted Pink with a Twist to Empower Women Through Education and Advocacy

Event to Showcase 2008 Olympic Gymnasts and Grammy Award-Winning Music Icons in Cancer Awareness Campaign CHICAGO, June 2 /PRNewswire-USNewswire/ -- This year in the United States an estimated 260,000 women will be diagnosed with breast, cervical, endometrial, ovarian, vaginal, and vulvar ca...
ASCO in Medical Technology

Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting

Carfilzomib Achieves 26 Percent Clinical Benefit Response Rate in Phase 2 Trial of Relapsed and Refractory Multiple Myeloma Patients - Proteolix Expands Trial ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., June 1 /PRNewswire/ -- Proteolix, Inc. today presented results from the company's most ...

Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting

Promising Anti-cancer Activity Observed in Relapsed Patients ORLANDO, Fla., and SOUTH SAN FRANCISCO, Calif. , May 30 /PRNewswire/ -- Proteolix, Inc. today reported on clinical advances for its carfilzomib solid tumor program in an oral presentation at the 2009 Annual Meeting of the American S...

Chipscreen and HUYA Bioscience to Present Clinical Data on Novel HDAC Inhibitor at the 2009 ASCO Annual Meeting

SHENZHEN, China and SAN DIEGO, May 28 /PRNewswire/ -- Shenzhen Chipscreen Biosciences, Ltd., and HUYA Bioscience International, LLC, today announced that final data from a Phase 1 trial conducted by Chipscreen of the investigational compound chidamide (CS055/HBI-8000) will be presented at the 2009...

Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types

- Oral presentation on Sandostatin(R) LAR Depot Phase III data shows significant antitumor benefit in patients with advanced neuroendocrine tumors of the midgut - Early data show that at eight weeks of treatment, Afinitor(R) stabilized or reduced tumor size in 61% of patients with advanced...

Kinex Pharmaceuticals To Present at ASCO 2009 Annual Meeting

BUFFALO, N.Y., May 27 /PRNewswire/ -- Kinex Pharmaceuticals will present results from a Phase 1 clinical study with KX2-391, at the ASCO 2009 Annual Meeting in Orlando, on May 29, 2009. The study was carried out at MD Anderson, Roswell Park Cancer Institute (RPCI) and Fox Chase Cancer Center. Dr...

TRACON Pharmaceuticals' Small Molecule TRC102 and Antibody TRC105 to be Presented at ASCO 2009

SAN DIEGO, May 26 /PRNewswire/ -- TRACON Pharmaceuticals, a biotechnology company that develops targeted therapies for oncology and related diseases, announced today that Phase 1 clinical results from studies of TRC105 and TRC102 in patients with advanced cancer will be presented at the American S...

Ascenta Therapeutics Announces Multiple Presentations on AT-101 at 2009 ASCO Annual Meeting

MALVERN, Pa., May 26 /PRNewswire/ -- Ascenta Therapeutics announced today that eleven presentations or publications on pre-clinical and clinical studies of AT-101, an oral, pan-Bcl-2 inhibitor, in several major tumor types will be made during the 2009 American Society of Clinical Oncology (ASCO) A...

Telik Announces Presentation at ASCO Annual Meeting

PALO ALTO, Calif., May 21 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK ) announced today that the results from the randomized clinical study of canfosfamide (TELCYTA(R), TLK286) in combination with pegylated liposomal doxorubicin (PLD) vs. PLD will be presented at the 45th annual meeting ...

Clinical Data on Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting

INDIANAPOLIS, May 19 /PRNewswire/ -- Semafore Pharmaceuticals, Inc., a privately held cancer drug discovery and development company, today announced that it will be reporting Phase I clinical data on its vascular targeted pan-PI3K/mTORC1/2 inhibitor, SF1126, during the 2009 American Society of Cli...

Boehringer Ingelheim to Present New Phase II Clinical Data on Two Lead Oncology Compounds at ASCO 2009

- Data on BIBW 2992, an Irreversible, Dual EGFR / HER2 Tyrosine Kinase Inhibitor, Suggests Activity in Second-line Treatment of NSCLC Patients with EGFR Activating Mutations - (1,2) -The First Presentation of Data on BIBF 1120 in Ovarian Cancer- RIDGEFIELD, Conn., May 14 /PRNewswire/ -- ...

More>>

ASCO in Biological News

Dana-Farber oncologists present at ASCO GU -- predict prostate cancer survival using Source MDx test

Orlando, Fla., February 27, 2009 Dana-Farber Cancer Institute (DFCI) and Source MDx today announced that Source MDx's whole blood RNA transcript-based Precision Profiles diagnostic test predicted survival in men with castration-resistant prostate cancer (CRPC). In a study of 62 CRPC patients, th...

New drug shows promise in treating drug-resistant prostate cancer

...n to begin what Jung described as "the pivotal Phase 3 clinical trials." The results of clinical studies with MDV3100 were described at the 2009 asco Genitourinary Cancer Symposium in February by the trials' principal investigator, Dr. Howard Scher of Memorial Sloan-Kettering Cancer Center. In gener...

Chromosome Deletion Predicts Aggressive Neuroblastoma

...l survival rate of 66 percent, compared to 83 percent for patients without the deletion. Dr. Attiyeh's research abstract received top honors at the asco meeting, by being named the top abstract among more than 100 submitted by oncology fellows. It also received a second award, as the highest-ranking ab...
ASCO in Biological Technology

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

- Interim Primary Endpoint Data from Phase II Study Shows 71% Objective Tumor Response Rate in Evaluable Patients Receiving Bavituximab Plus Docetaxel - - Secondary Endpoint Evaluation Shows Promising 7.4 Month Median Progression Free Survival in Initial Study Cohort - ORLANDO, Fla. and ...

PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer

KVISTGAARD, Denmark, June 1 /PRNewswire-FirstCall/ -- Detailed data from a randomized Phase 2 study with PROSTVAC(TM) were presented Saturday at the ASCO Annual Meeting in Orlando. The presentation was made by Philip Kantoff MD, Professor of Medicine, Harvard Medical School , and the Dana-Far...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

MALVERN, Pa., June 1 /PRNewswire/ -- Ascenta Therapeutics announced today that promising results from ongoing clinical studies in prostate, brain and lung cancers were among the data presented on AT-101, an oral, pan-Bcl-2 inhibitor, at the 2009 American Society of Clinical Oncology (ASCO) Annual ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at ASCO Annual Meeting

CALGARY, June 1 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY ) announced that interim results of a Phase II study of intravenous REOLYSIN(R) in patients with sarcomas metastatic to the lung were presented May 30, 2009 at the American Society of Clinical Oncology (ASCO...

Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel

Data indicate target-dependent activity in breast cancer patients with high expression of EpCAM ORLANDO, Fla., June 1 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and ...

AEterna Zentaris Presents Data Supporting Evaluation of AEZS-108 in Prostate Cancer at ASCO Meeting

QUEBEC CITY, June 1 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (TSX: AEZ; Nasdaq: AEZS ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that it presented results supporting the evaluation of its targeted cytotoxic peptide conjugate compound, AE...

YM BIOSCIENCES ANNOUNCES RESULTS OF RANDOMIZED NIMOTUZUMAB STUDY TO BE PRESENTED IN A POSTER AT ASCO ANNUAL MEETING

MISSISSAUGA, ON, May 28 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: YMI , TSX:YM, AIM:YMBA), an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that a poster presentation will report results from a randomiz...

Quest Diagnostics to Present Genomic Studies Related to New Testing Techniques for Leukemia and Prostate Cancer at 2009 ASCO Meeting

MADISON, N.J., May 28 /PRNewswire-FirstCall/ -- Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Socie...

Clinical Data on Peregrine's Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting

- Oral Presentation to Highlight Data from Phase II Study Evaluating Bavituximab in Advanced Breast Cancer - - Poster Presentation to Discuss Data from Phase I Study Evaluating Bavituximab in Multiple Tumor Types - TUSTIN, Calif., May 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceutical...

OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009

BOTHELL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI ) announced today that the Company will hold a live webcast and conference call of presentations made at an OncoGenex hosted reception during the 2009 American Society of Clinical Oncology An...
ASCO in Biological Dictionary

Cancer

...s, cancer detection and prevention, and treatment options. ... Cancer is a group of more than 100 ... Doctor-approved cancer information from asco | Cancer .Net - The American Society ... Information, Tools, and Resources to Help Manage the Cost of Cancer Care ... Podcast: prevent cancer ...
Other Tags
(Date:8/20/2014)... Dennis Thompson HealthDay Reporter ... birth rates fell dramatically during the past two decades, plummeting ... government report shows. An estimated 4 million fewer births ... to researchers from the U.S. Centers for Disease Control and ... me from the report," said Bill Albert, chief program officer ...
(Date:8/20/2014)... Bottom Line: Less than 42 percent of women ... and the factors associated with foregoing reconstruction included ... being older. , Author: Monica Morrow, M.D., of ... and colleagues. , Background: The Women,s Health and ... for breast reconstruction following a mastectomy. Still, most ...
(Date:8/20/2014)... vaccines is now, Free content, The time to ... commentary being published early online today in ... Yale School of Public Health write that the relentless ... outbreak represent a public health crisis that shows no ... have been developed in the last decade, yet the ...
(Date:8/20/2014)... Barbara Bronson Gray HealthDay ... Although it,s extremely rare, colds, flu and other minor ... risk for stroke in children, a new study suggests. ... stroke in the United States, said Dr. Heather Fullerton, lead ... pediatrics at the University of California, San Francisco Benioff Children,s ...
(Date:8/20/2014)... Reinberg HealthDay Reporter WEDNESDAY, ... cancer cells grow may help doctors diagnose and treat the ... investigators have found that the deadliest skin cancers occur most ... a long history of sun exposure. These lesions also ... Rapid cell growth -- called "high mitotic rate" -- ...
Breaking Medicine News(10 mins):Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 2Health News:Teen Birth Rate Has Dropped Dramatically in Last Two Decades: CDC 3Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:News from Annals of Internal Medicine 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 2Health News:High-Risk Melanomas Often on Head or Neck, Study Finds 3
(Date:8/19/2014)... MA -- MIT chemical engineers have devised a new ... are released slowly over a few weeks. When applied ... the body to rapidly form new bone that looks ... type of coated scaffold could offer a dramatic improvement ... involves transplanting bone from another part of the patient,s ...
(Date:8/19/2014)... born with neonatal abstinence syndrome (NAS) secondary to ... going through withdrawal than others, but the underlying ... epigenetic (when genes are turned on or off) ... researchers at Boston University School of Medicine (BUSM) ... of its kind study to identify some of ...
(Date:8/19/2014)... seas during warm phases and became extinct during cold ... a link between marine crocodilian diversity and the evolution ... 140 million years. , The research, led by ... and formerly from the University of Bristol, UK is ... crocodiles are ,cold-blooded, animals that mainly live in fresh ...
Breaking Biology News(10 mins):Engineering new bone growth 2Engineering new bone growth 3In-utero methadone, Subutex exposure could alter gene expression, cause severe Neonatal Abstience Syndrome 2Evolution of marine crocodilians constrained by ocean temperatures 2
Other Contents